Jonathan Biller - 06 Feb 2024 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP and Chief Legal Officer
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
06 Feb 2024
Net transactions value
$0
Form type
4
Filing time
08 Feb 2024, 16:28:57 UTC
Previous filing
03 Oct 2023
Next filing
13 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +6,294 +60% $0.000000 16,863 06 Feb 2024 Direct F1
transaction VRTX Common Stock Award $0 +4,743 +28% $0.000000 21,606 07 Feb 2024 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest in installments beginning on 02/10/2024.
F2 Restricted stock unit award that vests in installments beginning on 02/17/2025.